- Testing capacity is nearly impossible to increase as autumn approaches, the biggest laboratory in the U.S. says.
- Flu season could make the pandemic harder to get under control.
- Vaccine progress may not be enough to sustain the stock market recovery in the short-term.
From Moderna in the U.S. to Oxford in the U.K., the race for a vaccine is speeding up. The stock market has rallied repeatedly in response to favorable trial results. Unfortunately, a new threat has begun to emerge.
While testing has exploded since the onset of the pandemic, the biggest commercial laboratory in the U.S. warns capacity is reaching its limits.
According to James Davis, the executive vice president of general diagnostics at Quest Diagnostics, it will be virtually impossible for U.S. labs to increase testing capacity ahead of an expected demand spike when flu season arrives in the fall.
And if lackluster testing cripples the country’s ability to respond to the pandemic, it could affect the stock market.
A Vaccine May Be a Long-Term Solution, But Testing Is a Problem Right Now
A common theme among countries that have successfully gotten their local outbreaks under control is efficient testing and tracing.
South Korea, Taiwan, and New Zealand meticulously traced infected individuals to stop the virus from spreading. All three countries have subsequently opened their economies while the U.S. recovery hesitates.
The resumption of economic activity was a significant catalyst in the U.S. stock market’s second-quarter rally. After weeks of lockdown, many states allowed businesses to open with safety precautions in place.